ClearPoint Neuro, Inc.
NASDAQ:CLPTMedical - Devices
+$0.89 today
- Market cap
- $247.14M
- Beta
- 1.31
- P/E (TTM)
- -18.0
- EPS (TTM)
- -$0.98
Volume 0.64M
Average 0.67M
CLPT Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
ClearPoint Neuro, Inc.NASDAQ: CLPT
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables turns negative
Q1 FY2026 accounts receivables was -$2.02M, compared with $846K a year earlier. Trailing-twelve-month accounts receivables was -$3.13M. Over 3 fiscal years it compounded at +8.3% a year.
Context
- Accounts receivables amounted to 0.7% of revenue in FY2025, down 3.1 pp from a year earlier.
- Accounts receivables grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly accounts receivables holds near -$2.02M or moves back toward the trailing-twelve-month quarterly average of -$783.25K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (268K) USD
- Year-over-year change
- +77.8%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (268K) | +77.8% |
| FY2024 | 2024-12-31 | (1.21M) | +33.1% |
| FY2023 | 2023-12-31 | (1.8M) | -755.0% |
| FY2022 | 2022-12-31 | (211K) | -133.7% |
| FY2021 | 2021-12-31 | 627K | — |
Accounts Receivables vs competitors
How CLPT compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +159.8% is the 3rd highest of 8, against a peer median of -46.6%.
- Accounts receivables amounts to 7.7% of revenue for CLPT, versus a peer median of 0.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $5.5M USD | -46.6% | — | 0.8% | |
| LTM Mar 2026 | $5.26M USD | +166.0% | -38.3% | 0.6% | |
| LTM Mar 2026 | $4.72M USD | -7.3% | -22.4% | 2.3% | |
| LTM Apr 2026 | $3.7M USD | -169.8% | — | 0.4% | |
| LTM Mar 2026 | $3.56M USD | +210.9% | — | 1.7% | |
| LTM Mar 2026 | $3.13M USD | +159.8% | +8.3% | 7.7% | |
| LTM Mar 2026 | $1.97M USD | -94.6% | — | 0.8% | |
| LTM Mar 2026 | $1.1M USD | -82.4% | — | 1.3% | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | CA$0 CAD | — | — | 0.0% | |
| Peer median (excluding CLPT) | — | -46.6% | -30.3% | 0.8% | |
Competitors are the stored peer set for CLPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (14.41M) | (16.43M) | (22.09M) | (18.91M) | (25.54M) |
| Depreciation & Amortization | 692K | 777K | 1.51M | 1.9M | 982K |
| Deferred Income Tax | 202K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.08M | 4.13M | 6.08M | 6.91M | 8.18M |
| Change in Working Capital | (1.68M) | (4.29M) | (1.4M) | 1.4M | (9.81M) |
| Accounts Receivables | 627K | (211K) | (1.8M) | (1.21M) | (268K) |
| Inventory | (1.71M) | (4.42M) | 1.25M | 743K | (103K) |
| Accounts Payables | (762K) | 1.59M | 0 | 3.11M | (7.52M) |
| Other Working Capital | 165K | (1.25M) | (846K) | (1.24M) | (1.92M) |
| Other Non-Cash Items | 425K | 3.78M | 2.18M | (245K) | 2.27M |
| Operating Cash Flow | (12.7M) | (16.17M) | (13.72M) | (8.95M) | (23.93M) |
| Capital Expenditures | (168K) | (253K) | (717K) | (275K) | (522K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 1.14M |
| Purchases of Investments | 0 | (21.59M) | 0 | 0 | 0 |
| Sales of Investments | 0 | 12M | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 9.67M | 0 | 0 |
| Investing Cash Flow | (168K) | (10.74M) | 8.95M | (275K) | 615K |
| Debt Repayment | 0 | 0 | 0 | (10M) | 48.09M |
| Common Stock Issued | 46.79M | 745K | 0 | 16.15M | 3.95M |
| Common Stock Repurchased | 0 | 0 | (210K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 90K | (336K) | 506K | 40K | (1.86M) |
| Financing Cash Flow | 46.88M | 409K | 296K | 6.19M | 50.18M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 34.01M | (26.49M) | (4.48M) | (3.04M) | 26.87M |
| Free Cash Flow | (12.87M) | (16.42M) | (14.44M) | (9.23M) | (24.45M) |
ClearPoint Neuro, Inc.
NASDAQ:CLPT
Intrinsic Alpha fair value
Locked
Current Price
$7.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.